FDA Activates eCTD v4.0 Forward Compatibility for NDAs, ANDAs, BLAs, and INDs

Regulatory affairs teams managing active NDA, ANDA, BLA, IND, and Drug Master File dossiers now have a defined migration pathway: CDER and CBER began supporting eCTD v4.0 Forward Compatibility on October 16, 2026, allowing submissions originally filed under v3.2.2 to continue in v4.0 without restarting the application sequence. The change, published via FDA Federal Register Notice, is not yet a mandate, but it sets the operational clock running toward one.

Forward Compatibility means a sponsor can transition an existing v3.2.2 application to v4.0 mid-lifecycle, preserving submission history while adopting the updated standard. For regulatory operations teams, this is the window to audit current submission infrastructure, validate Electronic Submission Gateway configurations, and confirm that authoring tools are certified against the eCTD v4.0 Technical Conformance Guide. Teams relying on legacy v3.2.2 pipelines should treat this period as a structured remediation interval, not a grace period.

Both v3.2.2 and v4.0 remain supported formats under the FDA Data Standards Catalog as of this notice. FDA has stated it will issue advance notice before mandating eCTD v4.0 as the exclusive electronic submission format, but no timeline for that mandate has been published. Regulatory leads should monitor the Federal Register and the FDA Data Standards Catalog for version-specific effective dates, as updates are announced there before appearing in guidance documents.

Submission scope under the eCTD requirement remains unchanged: NDAs, ANDAs, BLAs, commercial INDs, and all subsequent amendments, supplements, and reports to those application types, including DMFs referenced against an IND, NDA, ANDA, or BLA, are subject to mandatory electronic submission standards. Noncommercial INDs, blood and blood component submissions, and Type III Master Files remain optional but encouraged under eCTD.

High-severity eCTD validation rules for both v3.2.2 and v4.0 are also active, per a separate FDA Federal Register Notice. Submissions that fail validation at the high-severity level risk rejection at the gateway, making pre-submission validation against current FDA specifications a non-negotiable step in any submission workflow.

The measurable checkpoint ahead is FDA's forthcoming advance notice on the v4.0-only mandate date, regulatory affairs leads who have not yet initiated internal readiness assessments against the v4.0 Submission Standards and Regional M1 specifications are operating with diminishing lead time.

Source: FDA CDER/CBER via FDA.gov eCTD page (What's New: Drugs RSS Feed), published October 29, 2026.